MedPath

Study for Monitoring the Impact of National HPV vaccinaTion program in Japan( Period II : April 2019-December 2026)

Not Applicable
Recruiting
Conditions
Cervical cancer and its precursor lesions
Registration Number
JPRN-UMIN000038883
Lead Sponsor
Showa University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
4000
Inclusion Criteria

Not provided

Exclusion Criteria

Individuals in either of the groups listed below will be excluded as subjects of the research 1. Female patients younger than 16 or older than 39 years 2. Female who do not have CIN, AIS or cervical cancer

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of HPV16/18 positives among subjects of cervical cancer, CIN2/3 and AIS in women aged 16-24, and 25-29 years
Secondary Outcome Measures
NameTimeMethod
1. The number of women aged 16-24, and 25-29 years who contract cervical cancer,CIN2/3, AIS 2. The proportion of HPV16/18 positives among subjects of CIN1 in women aged 16-24, and 25-29 years 3. The proportion of HPV16/18 positives among subjects of cervical cancer, CIN2/3 and AIS in women aged 16-39 years 4. The distribution of HPV types among subjects of cervical cancer, CIN1/2/3, and AIS in women aged 16-39 years 5. The number of women aged 16-39 years who contract cervical cancer, CIN2/3, and AIS 6. The proportion of HPV16/18 positives among women aged 16-39 years with CIN1 7. The number of deaths from cervical cancer among women aged 16-39 years
© Copyright 2025. All Rights Reserved by MedPath